WebinarsNew
Deep DiveNew
Explore Business Standard
WebinarsNew
Deep DiveNew
Explore Business Standard
The revenue stands at ₹4,516.60 crore, reflecting a quarter-on-quarter *(QoQ) increase of 8.23 per cent from ₹4,173.00 crore. This corresponds to a year-on-year *(YoY) growth of 2.25 per cent.
Operating Profit stands at ₹939.90 crore, reflecting a quarter-on-quarter *(QoQ) increase of 74.02 per cent from ₹540.10 crore. This corresponds to a year-on-year *(YoY) decline of 12.83 per cent.
PBDT stands at ₹760.90 crore, reflecting a quarter-on-quarter *(QoQ) increase of 70.03 per cent from ₹447.50 crore. This corresponds to a year-on-year *(YoY) decline of 17.57 per cent.
Profit Before Tax stands at ₹247.50 crore, reflecting a quarter-on-quarter *(QoQ) increase of 465.04 per cent from ₹-67.80 crore. This corresponds to a year-on-year *(YoY) decline of 49.16 per cent.
Net Profit stands at ₹198.60 crore, reflecting a quarter-on-quarter *(QoQ) increase of 483.40 per cent from ₹-51.80 crore. This represents a 56.77 per cent year-on-year *(YoY) decline for the same year.
| Category | Q4 FY25-26 | Q4 FY24-25 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,516.60 | 4,417.00 | 2.25 | 16,927.00 | 15,261.70 | 10.91 |
| Expenses | 3,576.70 | 3,338.80 | 7.13 | 13,874.60 | 12,095.40 | 14.71 |
| Other Income | 52.50 | 57.30 | -8.38 | 342.50 | 1,304.70 | -73.75 |
| Operating Profit | 939.90 | 1,078.20 | -12.83 | 3,394.90 | 4,471.00 | -24.07 |
| Depreciation | 513.40 | 436.30 | 17.67 | 1,956.70 | 1,687.00 | 15.99 |
| Interest | 231.50 | 212.40 | 8.99 | 990.30 | 897.40 | 10.35 |
| Profit Before Tax | 247.50 | 486.80 | -49.16 | 447.90 | 1,886.60 | -76.26 |
| Tax | 48.90 | 27.40 | 78.47 | 443.60 | 389.20 | 13.98 |
| Net Profit | 198.60 | 459.40 | -56.77 | 368.80 | 1,429.40 | -74.20 |
| Category | Q4 FY25-26 | Q4 FY24-25 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 604.70 | 643.80 | -6.07 | 2,346.40 | 2,242.60 | 4.63 |
| Expenses | 544.20 | 581.80 | -6.46 | 2,335.40 | 2,066.80 | 13.00 |
| Other Income | 49.80 | 62.70 | -20.57 | 319.70 | 849.80 | -62.38 |
| Operating Profit | 479.50 | 565.40 | -15.19 | 330.70 | 1,025.60 | -67.76 |
| Depreciation | 36.20 | 33.00 | 9.70 | 137.30 | 127.80 | 7.43 |
| Interest | 16.70 | 56.70 | -70.55 | 142.40 | 236.90 | -39.89 |
| Profit Before Tax | 57.40 | 35.00 | 64.00 | 51.00 | 660.90 | -92.28 |
| Tax | 6.40 | 13.80 | -53.62 | 12.00 | 50.50 | -76.24 |
| Net Profit | 51.00 | 21.20 | 140.57 | 37.20 | 609.30 | -93.89 |
| Category | Q4 FY25-26 | Q3 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,516.60 | 4,173.00 | 8.23 |
| Expenses | 3,576.70 | 3,632.90 | -1.55 |
| Other Income | 52.50 | 117.30 | -55.24 |
| Operating Profit | 939.90 | 540.10 | 74.02 |
| Depreciation | 513.40 | 515.30 | -0.37 |
| Interest | 231.50 | 209.90 | 10.29 |
| Profit Before Tax | 247.50 | -67.80 | -465.04 |
| Tax | 48.90 | -16.00 | -405.63 |
| Net Profit | 198.60 | -51.80 | -483.40 |
| Category | Q4 FY25-26 | Q3 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 604.70 | 621.30 | -2.67 |
| Expenses | 544.20 | 744.30 | -26.88 |
| Other Income | 49.80 | 74.80 | -33.42 |
| Operating Profit | 479.50 | 345.60 | 38.74 |
| Depreciation | 36.20 | 34.00 | 6.47 |
| Interest | 16.70 | 2.30 | 626.09 |
| Profit Before Tax | 57.40 | -84.50 | -167.93 |
| Tax | 6.40 | -8.10 | -179.01 |
| Net Profit | 51.00 | -76.40 | -166.75 |
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Biocon | -0.06% | -1.54% | 0.24% | 18.10% | 15.46% | 11.30% |
| Laurus Labs | 1.76% | 3.30% | 18.76% | 55.69% | 85.19% | 110.78% |
| Dr Reddy's Labs | 0.28% | 1.05% | -16.16% | -10.90% | -7.46% | -6.35% |
| Aurobindo Pharma | 0.47% | 1.86% | -0.91% | 14.80% | 30.34% | 44.77% |
| Alkem Lab | -1.07% | 1.81% | 2.78% | 7.43% | 1.90% | 17.27% |
| Glenmark Pharma. | 1.28% | 2.22% | -1.64% | -6.66% | 14.06% | 7.68% |
| Abbott India | 0.72% | -0.44% | 3.47% | 9.27% | 2.46% | -18.38% |
Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at Rs 198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of Rs 80.4 crore on various heads, including impact of new labour code. The company had posted a consolidated net profit of Rs 459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday. Consolidated revenue from operations in the fourth quarter was at Rs 4,516.6 crore as against Rs 4,417 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 4,241.2 crore as compared to Rs 3,987.5 crore in the same period a year ago, it said. The company's board has recommended a final dividend of 50 paise per equity share of face value of Rs 5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said. For FY26, consolidated net profit was at Rs 368.8 crore, down from Rs 1,4
